Imagion Biosystems (ASX:IBX) Cash And Cash Equivalents : A$2.67 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems Cash And Cash Equivalents?

Imagion Biosystems's quarterly cash and cash equivalents increased from Dec. 2023 (A$0.23 Mil) to Jun. 2024 (A$0.38 Mil) and increased from Jun. 2024 (A$0.38 Mil) to Dec. 2024 (A$2.67 Mil).

Imagion Biosystems's annual cash and cash equivalents declined from Dec. 2022 (A$4.45 Mil) to Dec. 2023 (A$0.23 Mil) but then increased from Dec. 2023 (A$0.23 Mil) to Dec. 2024 (A$2.67 Mil).

Imagion Biosystems Cash And Cash Equivalents Historical Data

The historical data trend for Imagion Biosystems's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems Cash And Cash Equivalents Chart

Imagion Biosystems Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

13.20

13.39

4.45

0.23

2.67

Imagion Biosystems Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial											4.45	0.45	0.23	0.38	2.67

Imagion Biosystems Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Imagion Biosystems (ASX:IBX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Imagion Biosystems Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Imagion Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

IBXXF:USA

Address

5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.imagionbiosystems.com

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines